0
Skip to Content
1nhaler
1nhaler
Home
About
News
Contact
1nhaler
1nhaler
Home
About
News
Contact
Home
About
News
Contact
1nhaler secures £1.5 million in funding to advance paper inhaler platform
Don Smith 17/11/2025 Don Smith 17/11/2025

1nhaler secures £1.5 million in funding to advance paper inhaler platform

Read More
Insider features 1nhaler as one of their Scottish businesses to watch in 2025
Don Smith 27/02/2025 Don Smith 27/02/2025

Insider features 1nhaler as one of their Scottish businesses to watch in 2025

Read More
1nhaler hires pharma industry leaders for key roles ahead of clinical trials
Don Smith 28/05/2019 Don Smith 28/05/2019

1nhaler hires pharma industry leaders for key roles ahead of clinical trials

Read More
Archangels invests £2 million in 1nhaler
Don Smith 28/05/2019 Don Smith 28/05/2019

Archangels invests £2 million in 1nhaler

Read More

1nhaler Ltd is registered in Scotland under the company registration number SC573454. VAT registration number 291 5368 80.

Registered office - 50 Lothian Road, Festival Square, Edinburgh, Scotland, EH3 9WJ

1nhaler Ltd is a drug-delivery platform developer, headquartered in Edinburgh and registered with Companies House, company number SC573454.

We work closely with pharmaceutical organisations and public health bodies helping to make life-saving drugs available to more people around the world.

We are committed to conducting our business ethically and with integrity, adopting a zero-tolerance approach to modern slavery and human trafficking.

We have implemented policies and procedures to ensure these practices do not occur in our own operations or in our supply chain, including clear expectations for suppliers. These include:

  • Equality and diversity, grievance & dispute and anti-harassment and bullying policies

  • Anti-bribery and corruption policy

  • Anti-slavery policy

  • Procurement policies requiring suppliers' compliance with all applicable laws and regulations.

Regular reviews, employee training and a whistleblowing channel support our commitment. Should any risk or non-compliance be identified, we will take prompt corrective actions.

This statement is produced in compliance with Section 54 of the Modern Slavery Act 2015. It has the full approval of the board of director for 1nhaler and is signed on their behalf by the CEO and director, Lisa McMyn, November 2026.